Michael J. Mullen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael J. Mullen has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Ageliki A. Karatza
Department of Paediatrics, University of Patras Medical School, Patras, Greece
1 shared publication Aikaterini Chamaidi
1 shared publicationAndrew Crean
1 shared publicationAndrew N. Redington
1 shared publicationAnji T. Yetman
1 shared publication- Anselm Uebing
Department of Congenital Heart Disease and Pediatric Cardiology, University Hospital Schleswig-Holstein, 24105 Kiel, Germany
1 shared publication
Latest Publications
- 1 January 2010
- Published by Elsevier
Contributors
- 1 November 2007
- Published by Taylor & Francis in Expert Review of Medical Devices
- Vol. 4 (6) , 781-792
BioSTAR®bioabsorbable septal repair implant
Thousands of patients have had congenital defects of their intra-atrial septa successfully closed via percutaneous techniques in the cardiac catheterization laboratory for hemodynamic correction, stroke, migraine and decompression illness. However, currently available closure technologies leave a permanent cardiac implant in a relatively young patient population. As the first device incorporating a bioabsorbable material for the treatment of structural heart disease, BioSTAR is uniquely designed to remodel into native tissue following closure, providing a more natural method of defect repair. This paper reviews atrial morphology, with a focus on patent foramen ovale, indications both present and emerging, and the development of technologies that promote a healthy natural healing response, with a focus on the design, testing and clinical experience with BioSTAR.
- 1 November 2007
- Published by Taylor & Francis in Expert Review of Medical Devices
- Vol. 4 (6) , 781-792
BioSTAR®bioabsorbable septal repair implant
Thousands of patients have had congenital defects of their intra-atrial septa successfully closed via percutaneous techniques in the cardiac catheterization laboratory for hemodynamic correction, stroke, migraine and decompression illness. However, currently available closure technologies leave a permanent cardiac implant in a relatively young patient population. As the first device incorporating a bioabsorbable material for the treatment of structural heart disease, BioSTAR is uniquely designed to remodel into native tissue following closure, providing a more natural method of defect repair. This paper reviews atrial morphology, with a focus on patent foramen ovale, indications both present and emerging, and the development of technologies that promote a healthy natural healing response, with a focus on the design, testing and clinical experience with BioSTAR.
- 18 May 2005
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 65 (2) , 306-309
Emergency stent graft deployment for acute aortic rupture following primary stenting for aortic coarctation
We present a case of endovascular stenting for aortic recoarctation complicated by acute aortic rupture, which was successfully treated by emergency stent graft deployment. This case illustrates the potential serious complication that can occur during aortic stent dilatation and how the prompt deployment of a stent graft helped to change the clinical outcome of this life‐threatening situation.
- 18 May 2005
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 65 (2) , 306-309
Emergency stent graft deployment for acute aortic rupture following primary stenting for aortic coarctation
We present a case of endovascular stenting for aortic recoarctation complicated by acute aortic rupture, which was successfully treated by emergency stent graft deployment. This case illustrates the potential serious complication that can occur during aortic stent dilatation and how the prompt deployment of a stent graft helped to change the clinical outcome of this life‐threatening situation.